Trial Profile
A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2017
Price :
$35
*
At a glance
- Drugs Enoxaparin sodium (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms RASTEN
- 02 Nov 2017 Protocol was amended to extend the study period due to a slower inclusion rate than initially expected, according to results published in the Annals of Oncology.
- 02 Nov 2017 Primary endpoint of significant increase of overall survival has not been met, according to results published in the Annals of Oncology.
- 02 Nov 2017 Results published in the Annals of Oncology